Vaxcyte/$PCVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Ticker
$PCVX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
414
ISIN
US92243G1085
Website
Vaxcyte Metrics
BasicAdvanced
$4.8B
-
-$3.98
1.20
-
Price and volume
Market cap
$4.8B
Beta
1.2
52-week high
$116.95
52-week low
$27.66
Average daily volume
1.5M
Financial strength
Current ratio
17.697
Quick ratio
17.235
Long term debt to equity
2.534
Total debt to equity
2.725
Profitability
EBITDA (TTM)
-626.907
Management effectiveness
Return on assets (TTM)
-14.53%
Return on equity (TTM)
-19.66%
Valuation
Price to book
1.51
Price to tangible book (TTM)
1.51
Price to free cash flow (TTM)
-8.058
Free cash flow yield (TTM)
-12.41%
Free cash flow per share (TTM)
-463.77%
Growth
Earnings per share change (TTM)
-5.64%
3-year earnings per share growth (CAGR)
21.78%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Bulls say / Bears say
Vaxcyte's VAX-31 vaccine candidate received FDA Breakthrough Therapy designation for adult indications, potentially expediting its development and approval process. (stocktitan.net)
The company successfully raised $1.5 billion through a public offering, significantly strengthening its financial position to support ongoing and future vaccine development programs. (finance.yahoo.com)
Vaxcyte's VAX-31 demonstrated a safety profile comparable to Pfizer's Prevnar 20 in a Phase 1/2 trial, indicating strong potential for competitive efficacy in the pneumococcal vaccine market. (seekingalpha.com)
Vaxcyte reported a net loss of $137.1 million for Q4 2024, reflecting the high costs associated with ongoing research and development activities. (stocktitan.net)
Insider selling activity, including the sale of 8,000 shares by COO Jim Wassil, may raise concerns about internal confidence in the company's short-term prospects. (techdows.com)
Despite positive developments, Vaxcyte's stock experienced a 3.24% decline following the announcement of its Q3 2024 financial results, suggesting potential investor apprehension regarding financial performance. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Vaxcyte News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $4.8B as of July 18, 2025.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of July 18, 2025.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.